Kidney transplantation across HLA and ABO antibody barriers

Current Opinion in Organ Transplantation

Volumn 18, Issue 4, 2013, Pages 445-454

  Becker, Luis E ^a   Süsal, Caner ^a   Morath, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ABO incompatible transplantation; crossmatch positive transplantation; desensitization; donor specific human leukocyte antigen antibodies

Indexed keywords

ALLOANTIBODY; BORTEZOMIB; ECULIZUMAB; IMMUNOGLOBULIN; RITUXIMAB;

ALLOGRAFT; ANTIBODY DETECTION; BLOOD GROUP ABO SYSTEM; DESENSITIZATION; HISTOCOMPATIBILITY; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOADSORPTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; PLASMA CELL; PLASMAPHERESIS; RECIPIENT; REVIEW;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUPING AND CROSSMATCHING; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84880916393     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283636c20     Document Type: Review

References (62)

1. Hume DM, Merrill JP, Miller BF, Thorn GW. Experiences with renal homotransplantation in the human: Report of nine cases. J Clin Invest 1955; 34:327-382
2. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-739
3. Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88:447-452
4. Roodnat JI, van de Wetering J, Claas FH, et al. Persistently low transplantation rate of ABO blood type O and highly sensitised patients despite alternative transplantation programs. Transpl Int 2012; 25:987-993
5. Fuggle SV, Johnson RJ, Bradley JA, et al. Impact of the 1998 UK National Allocation Scheme for deceased heartbeating donor kidneys. Transplantation 2010; 89:372-378
6. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725-1730
7. Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation 2009; 87:1246-1255
8. Fuchinoue S, Ishii Y, Sawada T, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011; 91:853-857
9. Morath C, Becker LE, Leo A, et al. ABO-incompatible kidney transplantation enabled by nonantigen-specific immunoadsorption. Transplantation 2012; 93:827-834
10. Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 2013; 95:852-858
11. Wilpert J, Fischer KG, Pisarski P, et al. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol Dial Transplant 2010; 25:3778-3786
12. Genberg H, Kumlien G, Wennberg L, Tyden G. The efficacy of antigenspecific immunoadsorption and rebound of anti-A/B antibodies in ABOincompatible kidney transplantation. Nephrol Dial Transplant 2011; 26:2394-2400
13. Flint SM, Walker RG, Hogan C, et al. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. Am J Transplant 2011; 11:1016-1024
14. Kohei N, Hirai T, Omoto K, et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12:469-476
15. Montgomery JR, Berger JC, Warren DS, et al. Outcomes of ABO-incompatible kidney transplantation in the United States. Transplantation 2012; 93:603-609
16. Takahashi K, Saito K. ABO-incompatible kidney transplantation. Transplant Rev (Orlando) 2013; 27:1-8
17. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: Longer-term outcomes. Am J Transplant 2009; 9:536-542
18. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13:76-85
19. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365:318-326
20. Morath C, Opelz G, Zeier M, Süsal C. Prevention of antibody-mediated kidney transplant rejection. Transpl Int 2012; 25:633-645
21. Morath C, Beimler J, Opelz G, et al. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 2010; 90:645-653
22. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO-and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006; 6:1829-1840
23. Iwasaki K, Miwa Y, Haneda M, et al. Significance of HLA class I antibodyinduced antioxidant gene expression for endothelial cell protection against complement attack. Biochem Biophys Res Commun 2010; 391:1210-1215
24. Chen Song S, Zhong S, Xiang Y, et al. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am J Transplant 2011; 11:2057-2066
25. Iwasaki K, Miwa Y, Ogawa H, et al. Comparative study on signal transduction in endothelial cells after anti-A/B and human leukocyte antigen antibody reaction: Implication of accommodation. Transplantation 2012; 93:390-397
26. Klein K, Süsal C, Schäfer SM, et al. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Atheroscler Suppl 2013; 14:199-202
27. Bartel G, Wahrmann M, Regele H, et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010; 10:2033-2042
28. Morath C, Beimler J, Opelz G. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012; 25:506-517
29. Thielke JJ, West-Thielke PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience. Transplantation 2009; 87:268-273
30. Stegall MD, Diwan T, Raghavaiah S. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405-2413
31. Alexandre GP, Squifflet JP, De Bruyère M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19:4538-4542; Transplantation. 2012; 94:738-743
32. Tydén G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5:145-148
33. Biglarnia AR, Nilsson B, Nilsson Ekdahl K. Desensitization with antigenspecific immunoadsorption interferes with complement in ABO-incompatible kidney transplantation. Transplantation 2012; 93:87-92
34. WahrmannM, Schiemann M, Marinova L, et al. Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. Nephrol Dial Transplant 2012; 27:2122-2129
35. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15:3256-3262
36. Alachkar N, Lonze BE, Zachary AA. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012; 94:165-171
37. Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 2012; 94:345-351
38. Randhawa PS, Schonder K, Shapiro R. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation 2010; 89:1462-1465
39. Sharif A, Alachkar N, Bagnasco S. Incidence and outcomes of BK virus allograft nephropathy among ABO-and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol 2012; 7:1320-1327
40. Alexander JW, First MR, Majeski JA, et al. The late adverse effect of splenectomy on patient survival following cadaveric renal transplantation. Transplantation 1984; 37:467-470
41. Uchida J, Iwai T, Machida Y. ABO-incompatible kidney transplantation in elderly patients over 60 years of age. Int Urol Nephrol 2012; 44:1563-1570
42. Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7:842-846
43. Perry DK, Burns JM, Pollinger HS. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9:201-209
44. Everly MJ, Everly JJ, Susskind B. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86:1754-1761
45. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89:277-284
46. Boothpur R, Torrence S, Brennan DC. Bortezomib does not reduce ABOisoagglutinin titers and may not be useful for ABO-incompatible transplant desensitization. Clin Transpl 2009; 491-493
47. Wahrmann M, Haidinger M, Körmöczi GF, et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89:1385-1390
48. Guthoff M, Schmid-Horch B, Weisel KC, et al. Proteasome inhibition by bortezomib: Effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol 2012; 26:171-175
49. Cascio P, Oliva L, Cerruti F. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol 2008; 38:658-667
50. Gonzá lez-Roncero F, Suñer M, Bernal G, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: Case reports. Transplant Proc 2012; 44:2690-2694
51. Noone D, Al-Matrafi J, Tinckam K, et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012; 12:2546-2553
52. Stewart ZA, Collins TE, Schlueter AJ, et al. Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc 2012; 44:3033-3036
53. ClinicalTrials.gov [Internet]. NCT01399593, Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization. Bethesda (MD): National Library of Medicine (US); 2012; Available from: Http://clinicaltrials.gov/ct2/show/NCT01399593. [Accessed 10 April 2013]
54. ClinicalTrials.gov [Internet]. Identifier: NCT01567085, safety & efficacy of eculizumab in the prevention of amr in sensitized recipients of a kidney transplant from a deceased donor. Bethesda (MD): National Library of Medicine (US); 2012; Available from: Http://clinicaltrials.gov/ct2/show/ NCT01567085. [Accessed 10 April 2013]
55. ClinicalTrials.gov [Internet]. Identifier: NCT01095887, Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi Bethesda (MD): National Library of Medicine (US); 2010; Available from: Http://clinicaltrials.gov/ct2/show/NCT01095887. [Accessed 10 April 2013]
56. ClinicalTrials.gov [Internet]. NCT01147302, A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection. Bethesda (MD): National Library of Medicine (US); 2010; Available from: Http://clinicaltrials.gov/ct2/show/NCT01147302. [Accessed 16 June 2013]
57. ClinicalTrials.gov [Internet]. NCT01134510, Safety & Tolerability of Berinert1 (C1 Inhibitor) Therapy to Prevent Rejection. Bethesda (MD): National Library of Medicine (US); 2010; Available from: Http://clinicaltrials.gov/ct2/ show/NCT01134510. [Accessed 10 April 2013]
58. Ferrari P, Fidler S, Holdsworth R, et al. High transplant rates of highly sensitized recipients with virtual crossmatching in kidney paired donation. Transplantation 2012; 94:744-749
59. Melcher ML, Blosser CD, Baxter-Lowe LA, et al. Dynamic challenges inhibiting optimal adoption of kidney paired donation: Findings of a consensus conference. Am J Transplant 2013; 13:851-860
60. Roodnat JI, Zuidema W, van de Wetering J, et al. Altruistic donor triggered domino-paired kidney donation for unsuccessful couples from the kidneyexchange program. Am J Transplant 2010; 10:821-827
61. Huh KH, Kim MS, Ju MK, et al. Exchange living-donor kidney transplantation: Merits and limitations. Transplantation 2008; 86:430-435
62. Rees MA, Kopke JE, Pelletier RP, et al. A nonsimultaneous, extended, altruistic-donor chain. N Engl J Med 2009; 360:1096-1101